Soleno Therapeutics (SLNO) Accumulated Expenses (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Accumulated Expenses data on file, last reported at $5.7 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $5.7 million, up 33.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.7 million (up 33.81% YoY), and the FY2025 annual result was $9.7 million, up 102.62% from the prior year.
• Accumulated Expenses declined to $5.7 million in Q1 2026 per SLNO's latest filing, from $9.7 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $9.7 million in Q4 2025 and troughed at $409000.0 in Q2 2025.
• A 5-year average of $2.9 million and a median of $1.7 million in 2022 frame the typical range for Accumulated Expenses.
• On a YoY basis, Accumulated Expenses climbed as much as 248.86% in 2025 and fell as far as 80.97% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $1.7 million in 2022, then jumped by 87.16% to $3.1 million in 2023, then soared by 52.34% to $4.8 million in 2024, then surged by 102.62% to $9.7 million in 2025, then slumped by 40.86% to $5.7 million in 2026.
• Business Quant data shows SLNO's Accumulated Expenses at $5.7 million in Q1 2026, $9.7 million in Q4 2025, and $7.2 million in Q3 2025.